ArticleMedical hypotheses2020
Inhaled hydroxychloroquine to improve efficacy and reduce harm in the treatment of COVID-19.
Article in Medical hypotheses, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 30 citations in OpenAlex.
- Phase I study in healthy participants to evaluate safety, tolerability, and pharmacokinetics of inhaled nezulcitinib, a potential treatment for COVID-19.Clinical and translational science · 2021Trial
- The In Vitro, In Vivo, and PBPK Evaluation of a Novel Lung-Targeted Cardiac-Safe Hydroxychloroquine Inhalation Aerogel.AAPS PharmSciTech · 2023Article
- Pulmonary drug delivery: an effective and convenient delivery route to combat COVID-19.Drug delivery and translational research · 2023Review
- Treatment of respiratory viral infections through inhalation therapeutics: Challenges and opportunities.Pulmonary pharmacology & therapeutics · 2022Review
- Antivirals and the Potential Benefits of Orally Inhaled Drug Administration in COVID-19 Treatment.Journal of pharmaceutical sciences · 2022Review
- Pulmonary Delivery of Hydroxychloroquine Nanostructured Lipid Carrier as a Potential Treatment of COVID-19.Polymers · 2022Article
- Iota-carrageenan extracted from red algae is a potent inhibitor of SARS-CoV-2 infection in reconstituted human airway epithelia.Biochemistry and biophysics reports · 2022Article
- Translational Modeling of Chloroquine and Hydroxychloroquine Dosimetry in Human Airways for Treating Viral Respiratory Infections.Pharmaceutical research · 2022Article
- Tolerability and pharmacokinetic evaluation of inhaled dry powder hydroxychloroquine in healthy volunteers.PloS one · 2022Article
- Targeted pulmonary drug delivery in coronavirus disease (COVID-19) therapy: A patient-specific in silico study based on magnetic nanoparticles-coated microcarriers adhesion.International journal of pharmaceutics · 2021Article
- Scoping insight on antiviral drugs against COVID-19.Arabian journal of chemistry · 2021Review
- Inhalation Delivery for the Treatment and Prevention of COVID-19 Infection.Pharmaceutics · 2021Review
- Recent updates in COVID-19 with emphasis on inhalation therapeutics: Nanostructured and targeting systems.Journal of drug delivery science and technology · 2021Review
- Exploring insights of hydroxychloroquine, a controversial drug in Covid-19: An update.Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association · 2021Review
- A retrospective comparison of drugs against COVID-19.Virus research · 2021Article
- Drug Repurposing in the COVID-19 Era: Insights from Case Studies Showing Pharmaceutical Peculiarities.Pharmaceutics · 2021Review
- Unraveling the origin of interactions of hydroxychloroquine with the receptor-binding domain of SARS-CoV-2 in aqueous medium.Chemical physics letters · 2021Article
- A Strategy to Treat COVID-19 Disease With Targeted Delivery of Inhalable Liposomal Hydroxychloroquine: A Preclinical Pharmacokinetic Study.Clinical and translational science · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Current formulations and dose regimens of hydroxychloroquine (HCQ) put patients at risk of harm. An analysis of clinical trials registered on ClinicalTrials.gov revealed that this may continue as many studies combine HCQ with agents that prolong the QT interval. Further, almost all of the trials registered do not consider dosage adjustment in the elderly, a patient population most likely to require HCQ treatment. Here we describe an inhaled formulation of HCQ which has passed safety studies in clinical trials for the treatment of asthma and discuss how this approach may reduce side-effects and improve efficacy. As this simple formulation progressed to phase II studies, safety data can be used to immediately enable phase II trials in COVID-19.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.